Submission Deadline: 30 December 2023 (Status: Open)
Special Issue Editor
Dr. Randhir Singh Dahiya Email | Website
Department of Pharmacology, Central University, Bathinda, India
Interests: herbal drugs; cardiovascular diseases; preclinical evaluation; clinical use; mechanism of action
Special Issue Information
Cardiovascular diseases (CVDs) are a cluster of disease affecting most of the population worldwide. Approximately 182 million cases of CVDs are reported worldwide every year. CVDs are also responsible for the development of other co-morbidities which further diminish patients' quality of life. CVDs have complex pathogenesis, and many factors are corelated with CVDs. Due to the complex pathogenesis, pharmacotherapy of CVDs is a challenge for medical fraternity. Moreover, comprehensive cure is not achieved in several cardiovascular diseases. Plethora of allopathic drugs are available for the treatment/management of CVDs but is associated with side effects and the cost of the therapy also limits the achievement of therapeutic goals.
Long term use of these allopathic drugs might result in some severe hidden side-effects which might turn out to be life-threatening later in life. Given these allopathic medicines related problems, scientists have focused research on an alternative therapy called Ayurveda or natural products that can be used to manage CVDs. According to scientific literature, a number of natural products are found to possess significant efficacy in the treatment of cardiovascular diseases at pre-clinical level. Still, these herbal drugs of natural products are not used as a first line therapeutic agent for the treatments of CVDs. Lack of specific mechanism of action and purity of herbal drugs are the major limitations for not considering herbal drugs as first line drugs. Considering this viewpoint, this special issue is focused on the utilisation of herbal drugs from pre-clinical system to clinical setups. This issue will comprise articles related to utilisation of herbal products for the treatment of CVDs, mechanism of action of herbal drugs in CVDs, clinical trials on herbal drug and regulatory guidelines for the use of herbal drugs for the treatment pf CVD and recent updates on the use of herbal drugs in clinical practice.
Randhir Singh Dahiya
herbal drugs; cardiovascular diseases; herbal drugs in clinical practice; mechanism of action of herbal drugs in CVDs; regulatory guidelines for herbals drugs
Manuscript Submission Information
Manuscripts should be submitted via our online editorial system at https://www.biolifesas.org/journalx_brha/authorLogOn.action by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. Submitted manuscripts should be well formatted in good English.